Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus ISONIAZID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus ISONIAZID.
ARIKAYCE KIT vs ISONIAZID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Inhibits mycolic acid synthesis in Mycobacterium tuberculosis via activation by catalase-peroxidase (KatG) to form reactive species that target InhA, a NADH-dependent enoyl-acyl carrier protein reductase.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
5 mg/kg orally once daily (max 300 mg/day) or 15 mg/kg orally twice weekly (max 900 mg/dose)
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
Clinical Note
moderateIsoniazid + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Isoniazid resulting in a loss in efficacy."
Clinical Note
moderateIsoniazid + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Isoniazid."
Clinical Note
moderateIsoniazid + Ketoconazole
"The serum concentration of Ketoconazole can be decreased when it is combined with Isoniazid."
Clinical Note
moderate1-4 hours (fast acetylators), 2-5 hours (slow acetylators); prolonged in hepatic impairment.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Renal (75-95% as metabolites and parent drug), fecal (<10%), biliary (minor).
Category C
Category A/B
Antimycobacterial
Antimycobacterial
Isoniazid + Itraconazole
"The serum concentration of Itraconazole can be decreased when it is combined with Isoniazid."